2019: Our year in numbers

  • 8% Revenue growth (both reported and constant currency rate)1
  • 22% Increase in pre-R&D operating profit to £11.3m (2018: £9.3m) as a result of sales growth and lower overhead cost growth (2018: £9.3m)
  • £27.4m Strong cash balance at 30 June 2019 (2018: £15.5m)
  • £3.5m Net profit for the year including Inflamax settlement of £6m (2018: Net loss of £7.5m)
  • Good growth across key countries and products with 0.5 point increase in market share2 in European business to 14.1% (2018: 13.6%)

Constant currency uses prior year weighted average exchange rates to translate current year foreign currency denominated revenue to give a year on year comparison excluding the effects of foreign exchange movements.

2 Market data and internal estimates for 12 months to 30 June 2019 for Allergy Therapeutics’ direct sales competitive markets excluding UK and Switzerland due to lack of competitor information.

Related links

link-img
Annual Report 2018

Click here to read this years Annual Report.

Annual Report 2018
link-img
Investors

Allergy Therapeutics Investor Relations Centre.

Overview
link-img
Get in touch

Contact us.

Get in touch